checkAd

    DGAP-News  433  0 Kommentare Evotec receives first milestone in Roche biomarker collaboration - Seite 2


    and expertise in key therapeutic areas including neuroscience, pain,
    metabolic diseases as well as oncology and inflammation. Evotec has
    long-term discovery alliances with partners including Bayer, Boehringer
    Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
    Roche and UCB. In addition, the Company has existing development
    partnerships and product candidates both in clinical and pre-clinical
    development. These include partnerships with Boehringer Ingelheim,
    MedImmune and Andromeda in the field of diabetes, with Janssen
    Pharmaceuticals in the field of depression and with Roche in the field of
    Alzheimer's disease. For additional information please go to
    www.evotec.com.


    FORWARD-LOOKING STATEMENTS - Information set forth in this press release
    contains forward-looking statements, which involve a number of risks and
    uncertainties. The forward-looking statements contained herein represent
    the judgement of Evotec as of the date of this report. Such forward-looking
    statements are neither promises nor guarantees, but are subject to a
    variety of risks and uncertainties, many of which are beyond our control,
    and which could cause actual results to differ materially from those
    contemplated in these forward-looking statements. We expressly disclaim any
    obligation or undertaking to release publicly any updates or revisions to
    any such statements to reflect any change in our expectations or any change
    in events, conditions or circumstances on which any such statement is
    based.


    Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
    +49.(0)40.56081-255, gabriele.hansen@evotec.com


    End of Corporate News

    ---------------------------------------------------------------------

    24.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
    company of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    DGAP's Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------


    Language: English
    Company: Evotec AG
    Manfred Eigen Campus / Essener Bogen 7
    22419 Hamburg
    Germany
    Phone: +49 (0)40 560 81-0
    Fax: +49 (0)40 560 81-222
    E-mail: info@evotec.com
    Internet: www.evotec.com
    ISIN: DE0005664809
    WKN: 566480
    Indices: TecDAX
    Listed: Regulierter Markt in Frankfurt (Prime Standard);
    Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
    München, Stuttgart


    End of News DGAP News-Service
    ---------------------------------------------------------------------
    264382 24.04.2014
    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Evotec receives first milestone in Roche biomarker collaboration - Seite 2 DGAP-News: Evotec AG / Key word(s): Miscellaneous Evotec receives first milestone in Roche biomarker collaboration 24.04.2014 / 07:29 --------------------------------------------------------------------- Hamburg, Germany - 24 April 2014: Evotec AG …

    Schreibe Deinen Kommentar

    Disclaimer